{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:04:16Z","timestamp":1790057056789,"version":"4.0.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) and chronic hypersensitivity pneumonitis are characterised by progressive structural lung damage, declining respiratory function, and limited regenerative treatment options. Platelet-rich plasma (PRP) possesses anti-inflammatory and regenerative properties; however, its pulmonary application remains largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 70-year-old man with a longstanding history of COPD and chronic hypersensitivity pneumonitis underwent eight treatments with nebulized autologous PRP at approximately 4-week intervals. In this observational case report, changes during the treatment period were assessed using serial clinical CT imaging with quantitative analysis, pulmonary function testing, home peak expiratory flow (PEF) and patient-reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At follow up, qCT demonstrated a decrease in low attenuation area percentage (LAA%) from 17.4% to 13.6%, representing a 22% relative reduction, accompanied by an 11.5% reduction in total inspiratory lung volume. Formal spirometry PEF increased by approximately 20% compared to the most recent pre-treatment assessment, with similar increases observed on home PEF monitoring. The patient also reported marked reductions in exertional dyspnea, substantially improved walking tolerance, and increased energy levels. Nebulized PRP was well tolerated, with no adverse events attributed to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our knowledge, this is the first report describing serial qCT assessment alongside physiological and patient-reported outcomes following nebulized autologous PRP in an individual with COPD and chronic hypersensitivity pneumonitis. Although causality cannot be established from a single case, the findings across multiple outcome domains warrant further investigation in prospectively designed studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1939351","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:02Z","timestamp":1790055542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Nebulized autologous platelet-rich plasma associated with quantitative CT and clinical changes in a patient with COPD and chronic hypersensitivity pneumonitis"],"prefix":"10.3389","volume":"13","author":[{"given":"Zane","family":"Sherif","sequence":"first","affiliation":[{"name":"Mermaid Beach Radiology","place":["Gold Coast, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Forbes","sequence":"additional","affiliation":[{"name":"Mermaid Beach Radiology","place":["Gold Coast, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirralee","family":"Sherif","sequence":"additional","affiliation":[{"name":"Mermaid Beach Radiology","place":["Gold Coast, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"207","author":"Agust\u00ed","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"210169","DOI":"10.1183\/16000617.0169-2021","article-title":"Diagnosis, course and management of hypersensitivity pneumonitis","volume":"31","author":"Hamblin","year":"2022","journal-title":"Eur Respir Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e33265","DOI":"10.7759\/cureus.33265","article-title":"Platelet-rich plasma treatment for chronic respiratory disease","volume":"15","author":"Knight","year":"2023","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1738044","DOI":"10.3389\/fmed.2025.1738044","article-title":"Case report: nebulized platelet-rich plasma facilitates resolution of post-infective pulmonary consolidation and cavitation in a lung cancer survivor","volume":"12","author":"Sherif","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.arthro.2012.04.148","article-title":"Platelet-rich plasma: the PAW classification system","volume":"28","author":"DeLong","year":"2012","journal-title":"Arthroscopy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1007\/s00330-019-06577-y","article-title":"Quantitative CT detects progression in COPD patients with severe emphysema in a 3-month interval","volume":"30","author":"Konietzke","year":"2020","journal-title":"Eur Radiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1148\/radiol.2015141579","article-title":"CT-definable subtypes of chronic obstructive pulmonary disease: a statement of the Fleischner Society","volume":"277","author":"Lynch","year":"2015","journal-title":"Radiology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1164\/rccm.202410-2012SO","article-title":"The use of computed tomography densitometry for the assessment of emphysema in clinical trials: a position paper from the Fleischner Society","volume":"211","author":"San Jos\u00e9 Est\u00e9par","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4104\/pcrj.2013.00025","article-title":"No room to breathe: the importance of lung hyperinflation in COPD","volume":"22","author":"Thomas","year":"2013","journal-title":"Prim Care Respir J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1148\/radiol.10091446","article-title":"Pulmonary emphysema: effect of lung volume on objective quantification at thin-section CT","volume":"257","author":"Madani","year":"2010","journal-title":"Radiology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1183\/09059180.00010002","article-title":"Physiology and consequences of lung hyperinflation in COPD","volume":"15","author":"O\u2019Donnell","year":"2006","journal-title":"Eur Respir Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.3390\/ijms21207794","article-title":"Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020","volume":"21","author":"Everts","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B13","first-page":"203","article-title":"The efficacy of autologous nebulized platelet rich plasma (PRP) as an early adjuvant therapeutic and prognostic treatment modality in the management of inhalation lung injury","volume":"43","author":"Metwally Salama","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33425\/2639-9512.1027","article-title":"Regenerative therapy for chronic obstructive pulmonary disease, a retrospective study of benefits and safety","volume":"2","author":"Coleman","year":"2018","journal-title":"Stem Cell Regen Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46889\/JRMBR.2021.2101","article-title":"Longitudinal assessment of FEV1 change following autologous cellular therapy","volume":"2","author":"Rubio","year":"2021","journal-title":"J Reg Med Biol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46889\/JRMBR.2021.2201","article-title":"Platelet rich plasma- platelet concentrate therapy in COPD: an observational cohort study","volume":"2","author":"Rubio","year":"2021","journal-title":"J Reg Med Biol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5531873","DOI":"10.1155\/2021\/5531873","article-title":"Phase I\/II clinical trial of autologous activated platelet-rich plasma (aaPRP) in the treatment of severe coronavirus disease 2019 (COVID-19) patients","volume":"2021","author":"Karina","year":"2021","journal-title":"Int J Inflam"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9427978","DOI":"10.1155\/2021\/9427978","article-title":"The effect of intravenous autologous activated platelet-rich plasma therapy on \u201cprofibrotic cytokine\u201d IL-1\u03b2 levels in severe and critical COVID-19 patients: a preliminary study","volume":"2021","author":"Karina","year":"2021","journal-title":"Scientifica (Cairo)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/ijms22041856","article-title":"Platelet lysate nebulization protocol for the treatment of COVID-19 and its sequels: proof of concept and scientific rationale","volume":"22","author":"Beitia","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101078","DOI":"10.1016\/j.reth.2026.101078","article-title":"Leukocyte-rich versus leukocyte-poor platelet-rich plasma for osteoarthritis: a systematic review","volume":"31","author":"Mart\u00edn-Vega","year":"2026","journal-title":"Regen Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1939351\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:39:03Z","timestamp":1790055543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1939351\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1939351"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1939351","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1939351"}}